

Major bleeding events in Jordanian patients undergoing percutaneous coronary intervention (PCI): Incidence, associated factors, impact on prognosis, and predictability of the CRUSADE bleeding risk score. Results from the First Jordanian PCR (PCR1)

Mohamad Jarrah, Ayman Hammoudeh¹, Osama Okkeh¹, Yousef Khader², Sahem Gharaibeh, Laith Nasser, Amro Rasheed³, Ayed Al-Hind³, Mohammad Mohealdeh³, Haneen Kharabsheh, Hanan Abunimeh⁴, Enas Hijjeh⁴, Lina Tashman⁴, Delia Omar⁴, Nadeen Kufoor⁵, on behalf of the First Jordanian PCI Registry Investigators Group

Division of Cardiology, Internal Medicine Department, King Abdullah University Hospital, Jordan University of Science and Technology; Irbid-Jordan
¹Interventional Cardiology Service, Istishari Hospital; Amman-Jordan, ²Faculty of Medicine, Jordan University of Science and Technology; Irbid-Jordan
³Department of Cardiology, Islamic Hospital; Amman-Jordan, ⁴Pharmaceutical Services Department, Ibn Haitham Hospital; Amman-Jordan
⁵Pharmaceutical Services Department, Arab Medical Center; Amman-Jordan

ABSTRACT

Objective: Determine the incidence of major bleeding events, their risk factors, and their impact on prognosis in Jordanian patients undergoing percutaneous coronary intervention (PCI). Evaluate the ability of the CRUSADE bleeding risk score (BRS) to predict major bleeding.

Methods: Major bleeding events were defined according to the CRUSADE classification and their incidence was evaluated from hospital admission to one year of follow up. The CRUSADE bleeding risk score was calculated for each patient during the index admission. Incidence of major bleeding events was evaluated in each of the bleeding score quintiles. JoPCR1 is a prospective, observational, multicenter registry of consecutive patients who underwent PCI at 12 tertiary care centers in Jordan. A case report form was used to record data prospectively at hospital admission, at discharge, and at 1 and 12 months of follow-up.

Results: The study included 2426 consecutive patients who underwent PCI. During the index hospitalization, major and minor bleeding events occurred in 0.95% and 2.6% of patients, respectively. Multivariate analysis showed that only two variables were significantly associated with major bleeding: female gender (OR=3.7; 95% CI 1.6, 8.5; p=0.002) and past history of cardiovascular disease (OR=2.6; 95% CI 1.1, 5.9; p=0.026). Patients who had in-hospital major bleeding events had higher cardiac mortality during index hospitalization (13.0% vs. 0.7%, p<0.005) and at one year of follow up (13.0% vs. 1.8%, p<0.005) compared to those who had no such events. Receiver operating characteristic curve analysis showed that the CRUSADE BRS has a high ability to predict major bleeding.

Conclusion: Major bleeding events were uncommon in this ME registry of a contemporary cohort of patients undergoing PCI but were associated with a higher mortality rate compared with those who did not have major bleeding events. CRUSADE BRS was highly predictive of the incidence of major bleeding events. (*Anatol J Cardiol* 2017; 17: 445-51)

Keywords: major bleeding events, percutaneous coronary intervention, CRUSADE bleeding risk score

Introduction

Bleeding is the most important non-ischemic complication after percutaneous coronary intervention (PCI) and can potentially lead to significant mortality and morbidity (1–3). Predicting the risk of major bleeding events in patients undergoing PCI is an essential component of an effective and safe PCI procedure (4, 5). Several bleeding risk scores (BRSs) including the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) BRS have been demonstrated to accurately predict

risks of major bleeding events (6–11).

The predictive value of the CRUSADE BRS might not apply to patients admitted with acute coronary syndrome (ACS) and/or undergoing PCI in regions other than those where the risk score was developed or tested due to differences in baseline clinical features and/or availability of medical and invasive therapeutic strategies. The objective of this study [the First Jordanian PCI Registry (JoPCR1)] was to determine the incidence of major bleeding events, their risk factors, and their impact on prognosis in Jordanian patients undergoing PCI. The ability of the CRUSADE BRS to predict major bleeding was also evaluated.

Address for correspondence: Mohamad Jarrah, Cardiology Section, Internal Medicine Department
 King Abdullah University Hospital, Jordan University of Science and Technology, Irbid-Jordan
 E-mail: Mijarrah@just.edu.jo

Accepted Date: 09.02.2017 **Available Online Date:** 22.03.2017

©Copyright 2017 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.com
 DOI:10.14744/AnatolJCardiol.2017.7530



Methods

JoPCR1 is a prospective, observational, multicenter registry of consecutive patients who underwent PCI at 12 tertiary care Amman Surgical Hospital, Amman, Jordan; Arab Medical Center, Amman, Jordan; Essra Hospital, Amman, Jordan; Ibn Haitham Hospital, Amman, Jordan; Islamic Hospital, Amman, Jordan; Istishari Hospital, Amman, Jordan; Jordan Hospital, Amman, Jordan; Jordan University Hospital, Amman, Jordan; Khalidi Medical Center, Amman, Jordan; King Abdullah University Hospital, Irbid, Jordan; Prince Hamza Hospital, Amman, Jordan; Specialty Hospital, Amman, Jordan, in two major cities of Jordan (Amman and Irbid) between January 2013 and February 2014. A case report form was used to record data prospectively at hospital admission, at discharge, and at 1 and 12 months of follow-up. Data were collected during follow-up visits or phone calls to the patient, a household relative, or a primary care physician at 1, 6, and 12 months after discharge. The study was approved by the Institutional Review Board of each participating hospital. Baseline data included clinical, laboratory, electrocardiographic, echocardiographic, and coronary angiographic features. Details of the PCI procedure and its outcome were also recorded. Creatinine clearance (CrCl) was estimated using the Cockcroft-Gault equation (12).

All PCI procedures were performed according to current standard guidelines. The arterial access site, type and number of stents, and the use of intravenous glycoprotein inhibitors (GPI) IIb/IIIa inhibitors were left to the operator's discretion. All patients received dual oral antiplatelet therapy (aspirin and 300–600 mg clopidogrel or 180 mg ticagrelor loading dose, and a loading dose of unfractionated heparin (100 IU/kg body weight). The activated clotting time was maintained >300 seconds throughout or immediately at the conclusion of the PCI procedure. PCI was indicated for either ACS or stable coronary disease (SC). ACS was classified as (1) acute ST-segment elevation myocardial infarction (STEMI); defined by the presence of cardiac ischemic chest pain, ST-segment elevation of >2 mm in at least 2 contiguous leads on the 12-lead electrocardiogram (ECG), and elevated cardiac biomarkers (troponin or creatinine kinase-myocardial band) greater than the upper limit of the normal, or (2) non-ST elevation ACS (NSTEMI); defined by the presence of cardiac ischemic chest pain, ST-segment depression, inverted T wave or normal ECG, and elevated cardiac biomarkers as above, and (3) unstable angina (UA); defined by the presence of ischemic cardiac pain, ST-segment depression, inverted T wave or normal ECG, and no elevation of cardiac biomarkers on admission and 8–12 hours later. SC was defined by the presence of either (1) chronic stable angina (CSA); i.e., ischemic cardiac pain on effort that did not change in severity for the past 3 months, and absence of resting ECG ischemic changes or elevated cardiac biomarkers, or (2) silent ischemia (SI); defined by the absence of angina in the presence of signs of myocardial ischemia on ECG, echocardiography, or nuclear myocardial scan.

PCI for STEMI was (1) primary, i.e., PCI as reperfusion strategy with no thrombolysis, (2) rescue; after failure of thrombolysis, or (3) elective; after successful thrombolysis. PCI for NSTEMI was (1) urgent, i.e., done within 2 hours after admission for ongoing chest pain, hemodynamic instability, life-threatening ventricular arrhythmia, or heart failure, (2) early invasive; within 24 hours after admission, or (3) invasive; within 24–72 hours after admission.

Major bleeding events were defined according to the CRUSADE study classification (6) and included intracranial hemorrhage, retroperitoneal bleeding, haematocrit (Hct) drop >12% from baseline, any red blood cell (RBC) transfusion when baseline Hct was >28%, or any RBC transfusion when baseline Hct was <28% with witnessed bleeding. Minor bleeding was defined as any non-major bleeding. Cardiac mortality was defined as any death not attributed to a clear noncardiac cause.

The CRUSADE BRS was calculated for each patient by assigning certain number of points for weighted integers of each of the eight independent predictors of in-hospital major bleeding events. These predictors include the patient's features [gender, diabetes mellitus (DM), and peripheral arterial disease (PAD)], clinical variables [heart rate (HR), systolic blood pressure (SBP), and heart failure], and admission laboratory data (Hct and CrCl). The sum of these points comprises the patient's score that ranges from 1 to 100 (6). The scores of all patients were grouped into 5 quintiles, Q1; very low risk, Q2; low risk, Q3; intermediate risk, Q4; high risk, and Q5; very high risk. Incidence rates of major and minor bleeding events and cardiac mortality were assessed during admission and after 1 and 12 months of follow up.

Statistical analysis

Data were described using mean values [\pm standard deviation (SD)] for continuous variables, frequencies, and percentages for categorical variables. The differences between proportions were tested using chi-square tests and the differences between two means were analyzed using independent t-test. Multivariate analysis of factors associated with in-hospital major bleeding was performed using logistic regression analysis. The variables were included in the model step by step and those with $p < 0.10$ in the univariate analysis were included in the model. Receiver operating characteristic (ROC) curve analyses were used to examine the overall discriminatory power of CRUSADE BRS to predict in-hospital major bleeding. The overall performance of the CRUSADE BRS was assessed by calculating the area under the curve (AUC). A p value of < 0.05 was considered statistically significant. Statistical analyses were performed using the IBM SPSS 20 (SPSS Inc., Chicago, USA).

Results

Patients' characteristics

The study included 2426 consecutive patients who underwent PCI and were followed up for one year. Follow up information was obtained directly from patients in 92% (clinic visits in

Table 1. Demographic, clinical, and angiographic characteristics of the study patients

Feature	n	%
Age, years (mean±SD)	59.0±10.1	–
Females	500	20.6
Hypertension	1511	62.3
Diabetes mellitus	1168	48
Hypercholesterolemia	1184	48.8
Current smoker	1055	43.5
Past myocardial infarction	263	10.8
Past stroke	50	2.1
Peripheral arterial disease	21	0.9
Prior PCI	589	24.3
Prior coronary artery bypass surgery	84	3.5
Medications prior to admission		
Aspirin	1568	64.7
Clopidogrel	532	22.0
Ticagrelor	16	0.7
Oral anticoagulants	34	1.4
Statins	1266	52.2
Beta blockers	1150	47.5
Renin-angiotensin system blockers	987	40.8
Antidiabetic agents	846	34.9
ST-segment deviation	1181	48.6
Elevated serum cardiac biomarkers	970	40.0
LVEF <45%	302	12.5
Heart failure on admission	269	11.1
Diagnosis		
ACS	1870	77.1
STEMI	726	29.9
NSTEMI	306	12.6
UA	838	34.5
Stable coronary syndrome	556	22.9
Chronic stable angina	500	20.6
Silent ischemia	56	2.3
ACS - acute coronary syndrome; LVEF - left ventricular ejection fraction; NSTEMI - non-ST-segment elevation myocardial infarction; PCI - percutaneous coronary intervention; STEMI - ST-segment elevation myocardial infarction; UA - unstable angina		

45% and by phone calls in 47%), from primary care physicians in 6%, and from household relatives in 2%.

Their baseline demographic and clinical characteristics at admission are shown in Table 1. Of the whole group, 24.7% were <50 years old, 48% had DM, and 77.4% were overweight or obese. 77.1% had ACS as the admission diagnosis. Table 2 shows the coronary arteriography findings, PCI procedures and indications, and medications used during hospitalization and at discharge. The vascular access was the femoral ar-

Table 2. Frequency and distribution of factors related to the PCI procedures

Feature	n	%
Number of diseased coronary arteries		
1 coronary artery	1417	58.4
2 coronary arteries	718	29.6
≥3 coronary arteries	291	12.0
Number of coronary arteries treated with PCI		
1 coronary artery	1732	71.4
2 coronary arteries	568	23.4
≥3 coronary arteries	119	5.6
Left main coronary artery	28	1.2
Saphenous vein graft	25	1.0
Indications for PCI		
STEMI	736	30.3
Primary	398	16.4
Rescue	68	2.8
Elective	270	11.1
NSTEACS	1138	46.9
Urgent	30	1.2
Early invasive	368	15.2
Invasive	740	30.5
Stable coronary syndrome	550	22.7
Medications during hospitalization		
Aspirin	2404	99.1
Clopidogrel	1968	81.1
Ticagrelor	455	18.8
Thrombolytic agents	81	3.3
Glycoprotein IIb/IIIa inhibitors	327	13.5
Heparin	2362	97.4
Antidiabetic agents	940	37.7
Medications on discharge		
Aspirin	2397	99.5
Clopidogrel	1977	82.0
Ticagrelor	410	17.0
Oral anticoagulants	20	0.9
Statins	2358	97.9
Beta blockers	1924	79.8
Renin-angiotensin system inhibitors	1502	62.3
Vascular access		
Femoral	2353	97.0
Radial	54	2.2
Brachial	9	0.8
ACS - acute coronary syndrome; NSTEACS - non-ST-segment elevation acute coronary syndrome; PCI - percutaneous coronary intervention; STEMI - ST-segment elevation myocardial infarction		

tery in the majority of procedures. Dual antiplatelet agents and GPI were administered in 99% and 13.5% of patients, respectively. Only 3.3% of patients were treated with thrombolysis.

Table 3. Incidence rates of major and minor bleeding events among the studied patients

Bleeding events	During admission (2426 patients) n (%)	From discharge to 30 days (2387 patients) n (%)	From 1 to 6 months (2343 patients) n (%)	From 6 to 12 months (2297 patients) n (%)	All n
Major bleeding	23 (0.95%)	4 (0.17%)	1 (0.04%)	3 (0.13%)	31
ICH	2	0	0	1	3
Retroperitoneal	2	0	0	0	2
Transfusion-requiring	3	4	1	2	10
Hematocrit drop	16	0	0	0	16
Minor bleeding	64 (2.6%)	10 (0.42%)	1 (0.04%)	2 (0.08%)	77
Vascular access site	64	8	1	2	75
Hematuria	0	2	0	0	2

ICH - intracranial haemorrhage

Table 4. Incidence rates of in-hospital major bleeding according to important and significant variables in univariate analysis

Variable	Major bleeding during admission				P
	No		Yes		
	n	%	n	%	
Gender					0.001
Male	1914	99.4	12	0.6	
Female	489	97.8	11	2.2	
Age, year					0.017
≤65	1781	99.3	12	0.7	
>65	622	98.3	11	1.7	
Diabetes mellitus					0.050
Yes	1283	98.7	17	1.3	
No	1120	99.5	6	0.5	
Hypertension					0.014
No	912	99.7	3	0.3	
Yes	1491	98.7	20	1.3	
eGFR					0.017
<60	293	98.3	5	1.7	
60–89	674	98.4	11	1.6	
≥90	1434	99.5	7	0.5	
Past PCI					0.031
No	1824	99.3	13	0.7	
Yes	579	98.3	10	1.7	
Past CVD					0.090
No	1462	99.3	10	0.71	
Yes	941	98.6	13	1.4	

CVD - cardiovascular disease; eGFR - estimated glomerular filtration rate; PCI - percutaneous coronary intervention

Incidence rate of bleeding

The incidence rates of major and minor bleeding events among the studied patients are detailed in Table 3. During the index hospitalization,

major and minor bleeding events occurred in 0.95% and 2.6% of patients, respectively. Most of the major bleeding events were transfusion-requiring or associated with an Hct drop [19/23 (82.6%)]. All vascular access bleeding events were minor. In-hospital major bleeding among patients who received thrombolytic agents (2.5%) was not different from that among patients who did not receive thrombolysis (0.9%), p=0.39. At one year, the incidence rate of major bleeding events was 1.29%, which implied that only a small number of patients had bleeding events after discharge up to 1 year of follow up. Patients who had PCI for ACS had more major bleeding events than patients with stable coronary disease (1.1% vs. 0.5%), but this observation was not significant (p=0.53).

Factors associated with in-hospital major bleeding

The incidence rates of in-hospital major bleeding according to significant variables in univariate analysis are shown in Table 4. Major bleedings during hospitalization were significantly higher among females, patients older than 65 years, and those who have diabetes, hypertension, CrCl <90, or past PCI. Multivariate analysis showed that only two variables were significantly associated with major bleeding; female gender (OR=3.7; 95% CI 1.6, 8.5; p=0.002) and past history of cardiovascular disease (OR=2.6; 95% CI 1.1, 5.9; p=0.026).

Major bleeding and cardiac mortality

Patients who had in-hospital major bleeding events had higher cardiac mortality during index hospitalization (13.0% vs. 0.7%, p<0.005) and at one year of follow up (13.0% vs. 1.8%, p<0.005) compared to those who had no such events.

Predictive power of CRUSADE BRS

CRUSADE BRS ranged from 1 to 94 with a mean of 23.3 ± 13.8. Patients who developed in-hospital major bleeding had significantly higher CRUSADE score compared to those who had no bleeding (31.9% vs. 22.3%, p<0.005). The incidence of major bleeding events in each quintile of the CRUSADE score is shown in Table 5, and ranged from 0.4% in the lowest quintile to 1.8% in the highest quintile. There was a significant increasing trend

Table 5. CRUSADE bleeding risk score quintiles and in-hospital major bleeding events

Quintiles	Score points	Major bleeding n (%)
Very low (Q1)	<10	2 (0.4)
Low (Q2)	11–17	0 (0.0)
Moderate (Q3)	18–24	5 (1.1)
High (Q4)	24–33	7 (1.5)
Very high (Q5)	>33	9 (1.8)
<i>P</i> - trend 0.004		

Table 6. Differences in mortality between patients who developed major bleeding and those who did not

Death	Major bleeding				<i>P</i>
	Yes (n=23)		No (n=24030)		
	n	%	n	%	
In-hospital	3	13.0	16	0.7	<0.005
1-month death	3	13.0	27	1.1	<0.005
6-month death	3	13.0	36	1.5	<0.005
1-year death	3	13.0	44	1.8	<0.005

in the rate of bleeding with the higher quintiles of the CRUSADE score. ROC analysis showed that the CRUSADE score has a high ability to predict major bleeding events.

Furthermore, cardiac mortality during index hospitalization was higher among patients who had major bleeding and high scores (mortality 0% in the three lower quintiles, 14.3% in the high quintile, and 22.2% in the very high quintile, *p*-trend <0.0001).

Mortality among patients who had major bleeding events from hospital admission to one year of follow up was significantly higher than those who did not have major bleeding event (Table 6).

Discussion

This is the first study that evaluated the incidence, risk factors, and impact on prognosis of major bleeding events, and the CRUSADE BRS predictability in Jordanian patients undergoing PCI in Jordan. The main findings were: (1) major bleeding events are uncommon but are associated with higher in-hospital and one-year cardiac mortality compared with patients who did not have major bleeding, (2) most of the major bleeding events occurred during hospitalization, (3) several factors were associated with an increased risk of bleeding, but only female gender and past history of cardiovascular disease (CVD) were independent predictors of major bleeding in the multivariate analysis, and (4) CRUSADE BRS was highly predictive for the incidence of in-hospital major bleeding events.

Major bleeding events

Traditionally, the outcome after PCI has been evaluated by measuring the classical 3 endpoints of death, MI, and urgent re-

peat revascularization. Recently, bleeding has been integrated in outcome analysis of clinical studies and registries because periprocedural bleeding in patients undergoing PCI is associated with an increased risk of recurrent ischemic complications and can adversely affect both short- and long-term mortality (1-4, 13–17).

This study enrolled patients who underwent PCI; a risk factor for bleeding by itself. Moreover, the majority of the enrolled patients (77%) had ACS; another risk factor for bleeding and most of the patients who had PCI for stable coronary disease (23%) had several risk factors associated with increased bleeding risk. Despite this clinical background, the incidence of major bleeding events was low. It is essential to adopt strategies that can reduce the incidence of bleeding, including the usage of a BRS to estimate the risk of major bleeding events and identify high-risk patients, use of appropriate antiplatelet and antithrombotic agents with maximal antithrombotic profile and minimal bleeding risk, choice of arterial access site, types and sizes of devices used in the PCI procedure, ACT monitoring, and closer surveillance for bleeding after the procedure (18–25).

The list of risk factors for bleeding in patients admitted with ACS or who underwent PCI includes old age, female gender, hypertension, DM, lower body weight, prior vascular disease [PAD or stroke], higher HR, lower SBP, heart failure or cardiogenic shock, and lower baseline Hct and creatinine clearance, among others (26–29).

The incidence of in-hospital major bleeding in our study (0.95%) is lower than those reported by clinical studies of ACS patients (0.4–10%) and patients undergoing PCI (2.2–14%) (30). Plausible explanations of this low rate of bleeding include the young age of our patients and lower prevalence of comorbid diseases that are associated with high risk of bleeding including PAD, chronic renal disease and heart failure, and lower body weight. We observed a sharp decrease in the incidence of major bleeding events after discharge. Most of these events were minor vascular access hematomas that occurred in the first month of follow up.

The association of bleeding with excess long-term mortality in this study concurs with other studies and implies that bleeding is not simply a side effect of the medications and PCI procedure, or an acute event with no long-term prognostic impact (1, 25, 31). The excess bleeding-related mortality is multifactorial. These factors include the common risk factors mortality and bleeding share (age, diabetes mellitus, hypertension, past history of CVD, and renal insufficiency), hemodynamic effects of massive bleeding, higher mortality associated with intracranial bleeding, neurohormonal activation associated with hypotension, and bleeding-related imaging procedures and surgical interventions under general anesthesia that may independently increase cardiac mortality (32–38).

CRUSADE bleeding risk score

Clinical studies have shown that the CRUSADE BRS has a relatively high accuracy for estimating bleeding risk by incorpo-

rating admission and treatment variables. Although age is one of the predictors of major bleeding that is not directly considered in calculating the risk score, it is incorporated in calculating the CrCl. Each of the bleeding risk scores in clinical use has been utilized in specific patient population, including STEMI patients treated with fibrinolysis (GUSTO score) (39), STEMI and NSTEMI patients (GRACE score) (9), ACS patients planned to have urgent or early intervention (Phase III ACUITY study) (7), elective or urgent PCI via the femoral artery access (5), PCI with combination antiplatelet and antithrombotic agents (REPLACE 2 study) (40), and NSTEMI patients (CRUSADE study) (6).

The CRUSADE BRS was originally developed from NSTEMI patients' data, but its predictive value was unchanged when patients with UA were included. Moreover, analysis of the ACTION Registry-GWTG suggested that the CRUSADE BRS can be applied in STEMI patients (41). The CRUSADE BRS evaluated the score's predictability of in-hospital major bleeding events and mortality. Our study further demonstrated that this predictability persists up to one year after discharge, similar to other studies (25). The observed high predictability for major bleeding events of the CRUSADE BRS supports its expanded applicability in other geographical regions than those where the score was developed.

Study limitations

This registry had limitations inherent to observational studies (42). It may be subject to selection bias, collection of non-randomized data, and missing or incomplete information. Participation was voluntary and the enrolment of consecutive patients was encouraged, but this was not verified, as it is the case with similar registries (43). The accuracy of recall of the patients or their relatives of major events, such as major bleeding, is unlikely to be underreported. The registry included high volume tertiary care center; thus, it may not fully represent the PCI practice and outcome in all areas in the country or region.

Conclusions

Major bleeding events were uncommon in this Jordanian registry of a contemporary cohort of patients undergoing PCI but were associated with a higher mortality rate compared with those who did not have major bleeding events. CRUSADE BRS was highly predictive of the incidence of major bleeding events. We recommend incorporating CRUSADE BRS in the care of patients undergoing PCI to identify high-risk patients for bleeding events.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Authorship contributions: Concept – M.J., Y.K., A.H., L.N., L.T.; Design – M.J., A.H., S.G., H.A., E.H.; Supervision – M.J., Y.K., A.H., S.G., L.N., H.A., E.H., L.T., D.O.; Fundings – Novartis; Materials – M.J., A.H., O.O., S.G., L.N., H.K., H.A., E.H., L.T.; Data collection &/or processing – M.J.,

Y.K., A.H., A.A.H., O.O., S.G., D.O.; Analysis &/or interpretation – M.J., Y.K., A.H., O.O., D.O.; Literature search – M.J., A.H., O.O., A.A.H.; Writing – M.J., A.H., L.N., H.K.; Critical review – M.J., Y.K., A.H., H.K..

References

1. Erdem G, Flathe M. Assessing bleeding risk in acute coronary syndromes. *Rev Esp Cardiol* 2012; 65: 4-6. [CrossRef]
2. Subherwal S, Peterson ED, Dai D, Thomas L, Messenger JC, Xian Y, et al. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data Cath-PCI Registry. *J Am Coll Cardiol* 2012; 59: 1861-9. [CrossRef]
3. Chhatriwalla AK, Amin AP, Kennedy KF, House JA, Cohen DJ, Rao SV, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. *JAMA* 2013; 309: 1022-9. [CrossRef]
4. Kikkert WJ, Zwinderman AH, Vis MM, Baan J Jr, Koch KT, Peters RJ, et al. Timing of mortality after severe bleeding and recurrent myocardial infarction in patients with ST-segment-elevation myocardial infarction. *Circ Cardiovasc Interv* 2013; 6: 391-8. [CrossRef]
5. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. *Eur Heart J* 2007; 28: 1936-45. [CrossRef]
6. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. *Circulation* 2009; 119: 1873-82. [CrossRef]
7. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, et al. Association of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. *Eur Heart J* 2009; 30: 1457-66. [CrossRef]
8. Ariza-Sole A, Salazar-Mendiguchia J, Lorente V, Sanchez-Salado JC, Romaguera R, Ferreiro JL, et al. Predictive ability of bleeding risk scores in the routine clinical practice. *Eur Heart J Acute Cardiovasc Care* 2015; 4: 205-10. [CrossRef]
9. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J* 2003; 24: 1815-23. [CrossRef]
10. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011; 123: 2736-47. [CrossRef]
11. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. FACC 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013; 61: e78-e140. [CrossRef]
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31-41. [CrossRef]
13. Naruse Y, Sato A, Hoshi H, Takeyasu N, Kakefuda Y, Ishibashi M, et al. Cardiovascular Assessment Study (ICAS) Registry. Triple anti-thrombotic therapy is the independent predictor for the occurrence of major bleeding complications. Analysis of percent time in thera-

- peutic range. *Circ Cardiovasc Interv* 2013; 6: 444-51. [CrossRef]
14. Abraham NS, Hartman C, Richardson P, Castillo D, Street Jr. RL, Naik AD. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. *Circulation* 2013; 128: 1869-77. [CrossRef]
 15. Taylor J. Updated ESC Guidelines for managing patients with suspected non-ST-elevation acute coronary syndrome. *Eur Heart J* 2011; 32: 2909-10. [CrossRef]
 16. Fox KA, Carruthers K, Steg PG, Avezum A, Granger CB, Montalescot G, et al; GRACE Investigators. Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. *Eur Heart J* 2010; 31: 667-75. [CrossRef]
 17. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient Outcomes (PLATO trial). *Eur Heart J* 2011; 32: 2933-44. [CrossRef]
 18. Gehani AA, Al-Hinai AT, Zubaid M, Almahmeed W, Hasani MR, Yusufali AH, et al, for the INTERHEART Investigators in Middle East. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. *Eur J Prev Cardiol* 2014; 21: 400-10. [CrossRef]
 19. Hammoudeh AJ, Izraiq M, Hamdan H, Tarawneh H, Harassis A, Tabalat R, et al. High-sensitivity C-reactive protein is an independent predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome. CRP and prognosis in acute coronary syndrome. *International Journal of Atherosclerosis* 2008; 3: 50-5.
 20. Hammoudeh A, Ehtay A, Ghanem GY, Haddad J; CEPHEUS LEVANT Survey Investigators. Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholesterolemia (CEPHEUS) study. *Curr Med Res Opin* 2014; 30: 1957-65. [CrossRef]
 21. Marso SP, Amin AP, House JA, Kennedy KF, Spertus JA, Rao SV, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. *JAMA* 2010; 303: 2156-64. [CrossRef]
 22. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. *Am J Cardiol* 2005; 96: 1200-6.
 23. Verheugt FW, Steinhilb RS, Hamon M, Darius H, Steg PG, Valgimigli M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and non-access site bleeding in percutaneous coronary intervention. *J Am Coll Cardiol* 2011; 4: 191-7.
 24. Halg C, Brunner-La Rocca HP, Kaiser C, Jeger R, Osswald S, Pfisterer M, et al; BASKET investigators. Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulant therapy. *EuroIntervention* 2009; 5: 425-31.
 25. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. *J Am Cardiol* 2008; 51: 690-7. [CrossRef]
 26. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J* 2015; 36: 1762-71.
 27. Hasin T, Markiewicz W, Hammeman H, Aronson D. Prevalence and prognostic significance of transient, persistent, and new-onset anemia after acute myocardial infarction. *J Am Coll Cardiol* 2009; 54: 486-91. [CrossRef]
 28. Kwok CS, Sherwood MW, Watson SM, Nasir SB, Sperrin M, Nolan J, et al. Blood transfusion after percutaneous coronary intervention and risk of subsequent adverse outcomes. *J Am Coll Cardiol Intv* 2015; 8: 436-46. [CrossRef]
 29. Valente S, Lazzeri C, Chiostrì M, Sori A, Giglioli C, Gensini GF. Prior and new onset anemia in ST-elevation myocardial infarction: a different prognostic role? *Intern Emerg Med* 2011; 6: 329-36. [CrossRef]
 30. Pham PA, Pham PT, Pham PC, Miller JM, Pham PM, Pham SV. Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention. *Vasc Health Risk Manag* 2011; 7: 551-67.
 31. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: Position paper by the Working Group on Thrombosis of the European Society of Cardiology. *Eur Heart J* 2011; 32: 1854-64. [CrossRef]
 32. Robinson SD, Janssen C, Fretz EB, Chase A, Della Siega A, Carere RG, et al. Non-red blood cell transfusion as a risk factor for mortality following percutaneous coronary intervention. *Int J Cardiol* 2012; 157: 169-73. [CrossRef]
 33. Pilgrim TM, Wenaweser P. Impact of bleeding on clinical outcome in patients undergoing PCI. *Eur Heart J* 2010; 31(Suppl 1): 658.
 34. Sabatine MS, Morrow DA, Guigliano RP, Burton PB, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. *Circulation* 2005; 111: 2042-9. [CrossRef]
 35. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndrome. *Circulation* 2006; 114: 774-82. [CrossRef]
 36. Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, et al. Effect of switching anti-thrombotic agents for primary angioplasty in acute myocardial infarction. The HORIZONS-SWITCH analysis. *J Am Coll Cardiol* 2011; 57: 2309-16. [CrossRef]
 37. Dauerman HL, Rao SV, Resnic FS, Applegate RJ. Bleeding avoidance strategies. Consensus and controversy. *J Am Coll Cardiol* 2011; 58: 1-10. [CrossRef]
 38. Manoukian SV. The relationship between bleeding and adverse outcomes in ACS and PCI: pharmacologic and nonpharmacologic modification of risk. *J Invasive Cardiol* 2010; 22: 132-41.
 39. Yu J, Baber U, Kini A, Vlachojannis G, Sartori S, O'Neill B, et al. Comparison of bleeding definitions, BARC, GUSTO, TIMI and VARC in patients undergoing balloon aortic valvuloplasty: results from a two-center registry. *J Am Coll Cardiol* 2012; 59: E65. [CrossRef]
 40. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. *JAMA* 2003; 289: 853-63.
 41. Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry-GWTG. *Am J Cardiol* 2011; 107: 1136-43. [CrossRef]
 42. Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, et al; European Society of Cardiology. Management and outcome of patients with established coronary artery disease: Euro Heart Survey on coronary revascularization. *Eur Heart J* 2005; 26: 1169-79.
 43. Wong JA, Goodman SG, Yan RT, Wald R, Bagall AJ, Welsh RC, et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. *Eur Heart J* 2009; 30: 549-57. [CrossRef]